Search hospitals > South Carolina > Greenville

Prisma Health Cancer Institute - Butternut

Claim this profile
Greenville, South Carolina 29605
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
258 reported clinical trials
6 medical researchers
Photo of Prisma Health Cancer Institute - Butternut in GreenvillePhoto of Prisma Health Cancer Institute - Butternut in GreenvillePhoto of Prisma Health Cancer Institute - Butternut in Greenville

Summary

Prisma Health Cancer Institute - Butternut is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Prisma Health Cancer Institute - Butternut is involved with conducting 258 clinical trials across 453 conditions. There are 6 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.

Area of expertise

1Cancer
Global Leader
Prisma Health Cancer Institute - Butternut has run 97 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Prisma Health Cancer Institute - Butternut has run 49 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Prisma Health Cancer Institute - Butternut

Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Colon Cancer
Tumors
Bladder Cancer
Oropharyngeal Carcinoma
Pancreatic Neuroendocrine Tumors
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Support Program

for Breast Cancer

This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Prisma Health Cancer Institute - Butternut?
Prisma Health Cancer Institute - Butternut is a medical facility located in Greenville, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Prisma Health Cancer Institute - Butternut is involved with conducting 258 clinical trials across 453 conditions. There are 6 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.